PROGNOSTIC-SIGNIFICANCE OF MAGNETIC-RESONANCE-IMAGING IN PATIENTS WITH ASYMPTOMATIC MULTIPLE-MYELOMA

PROGNOSTIC-SIGNIFICANCE OF MAGNETIC-RESONANCE-IMAGING IN PATIENTS WITH ASYMPTOMATIC MULTIPLE-MYELOMA
复制标题

DOI:
10.1200/jco.1995.13.1.251
复制
发表时间:
1995-01-01
影响因子:
45.3
通讯作者:
ALEXANIAN, R
ALEXANIAN, R
中科院分区:
医学1区
文献类型:
--
作者:
MOULOPOULOS, LA;DIMOPOULOS, MA;ALEXANIAN, R

文献摘要

被引文献

相似文献

目的:为了评估新诊断的无症状多发性骨髓瘤患者的磁共振(MR)成像的预后意义,患者和方法:连续38例无症状骨髓瘤的低肿瘤质量和阴性骨骼调查进行了磁共振成像的胸腰骶椎。骨髓受累的存在和模式与标准实验室参数和疾病进展时间相关。结果:19例患者(50%)在脊柱MR成像中有骨髓受累的证据。骨髓受累的MR模式分为弥漫型(5例)、杂色型(9例)和局灶型(5例)。MRI检查异常的患者需要治疗的中位时间为16个月,而MRI检查正常的患者需要治疗的中位时间为43个月(P <0.01)。一项异常的脊柱MR研究发现,无症状的患者可能比MR正常的患者更早需要治疗。正常的MR模式为推迟化疗提供了额外的理由。然而,磁共振成像仍然是一种研究工具,以分期患者与多发性骨髓瘤,直到更多的数据积累。(C)1995年,美国临床肿瘤学会。
Purpose: To assess the prognostic significance of magnetic resonance (MR) imaging in patients with newly diagnosed asymptomatic multiple myeloma.Patients and Methods: Thirty-eight consecutive patients with asymptomatic myeloma of low tumor mass and negative skeletal surveys underwent MR imaging of the thoracic and lumbosacral spine. The presence and patterns of marrow involvement were correlated with standard laboratory parameters and time to disease progression.Results: Nineteen patients (50%) had evidence of marrow involvement at spinal MR imaging. MR patterns of marrow involvement were classified as diffuse (five patients), variegated (nine), and focal (five). Patients with abnormal MR imaging studies required therapy after a median of 16 months, versus 43 months for those with normal MR studies (P < .01).Conclusion: Abnormal marrow patterns were present in half of patients with asymptomatic myeloma. An abnormal MR study of the spine identified asymptomatic patients who were likely to require treatment earlier than those with a normal MR study. A normal MR pattern provided additional justification to defer institution of chemotherapy. However, MR imaging remains an investigational tool to stage patients with multiple myeloma until more data are accumulated.(C) 1995 by American Society of Clinical Oncology.